Firstly, any evidence that people are finding it easier now to get drugs that they are entitled to is to be welcomed, but a word of background: you may recall that, in 2014, Plaid Cymru announced a policy of seeking a new treatment fund that was specifically designed to fund the drugs obtained through individual patient funding requests. I'm very pleased that we are a step forward now, as a result of an agreement between the Government and Plaid Cymru on having exceptionality removed. I'm pleased that that has happened. Labour then, in 2016, announced its own new treatment fund, which wasn't the same. We were of the view—and it is important to point this out—that we shouldn't really need a fund to make LHBs do things that they ought to have been doing legally anyway, as welcome as additional funds are.

So, the first question to you: in the media this morning, it's been reported that, previously, officials suggested that it could take more than 100 days for an approved medicine to be rolled out. Is that an admission that the previous ministerial guidance that treatments should be available within three months following approval was being ignored? And, yes, there is additional funding through the new treatment fund for LHBs to pay for treatments, but it's worth asking this also: do you think that there's a risk, as a result of this policy, that LHBs will expect extra funds to implement other ministerial directions that they ought to legally be adhering to anyway?

Moving on to what you referred to as sustainable plans for the introduction of new medicines, perhaps you could elaborate a little bit on that; namely, how are you ensuring that this planning does take place, and that patients aren't left in the position of a drug not being available in the future?

And finally—it's a point I've raised on a number of occasions in the past—it isn't always just medicines that improve outcomes for patients. Other health technologies and sometimes even simple changes to guidance on how medicines are used can make a difference to patients. Increased awareness, even, of a condition can lead to better outcomes, and there are barriers here to the uptake of best practice across the NHS; for example, a lack of time for continuous professional development. Is this something that you would look at addressing also?